{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T10:46:13Z","timestamp":1783248373434,"version":"3.54.6"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272645"],"award-info":[{"award-number":["82272645"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172692"],"award-info":[{"award-number":["82172692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Key Technologies R&D Program of Songjiang District, Shanghai","award":["2024SJKJGG072"],"award-info":[{"award-number":["2024SJKJGG072"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04358-3","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T07:53:16Z","timestamp":1773474796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mast cell-derived MIF Polarizes Th17 cells to drive lung adenocarcinoma progression"],"prefix":"10.1007","volume":"75","author":[{"given":"Qianqian","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"key":"4358_CR1","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","volume":"20","author":"A Leiter","year":"2023","unstructured":"Leiter A, Veluswamy RR, Wisnivesky JP (2023) The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol 20:624\u2013639. https:\/\/doi.org\/10.1038\/s41571-023-00798-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4358_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00679-8","volume":"14","author":"C Yang","year":"2025","unstructured":"Yang C, Liu Y, Huang Z et al (2025) Recent advances and challenges of cellular immunotherapies in lung cancer treatment. Exp Hematol Oncol 14:94. https:\/\/doi.org\/10.1186\/s40164-025-00679-8","journal-title":"Exp Hematol Oncol"},{"key":"4358_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41571-025-01021-1","volume":"22","author":"Z Rahal","year":"2025","unstructured":"Rahal Z, El Darzi R, Moghaddam SJ et al (2025) Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol 22:463\u2013482. https:\/\/doi.org\/10.1038\/s41571-025-01021-1","journal-title":"Nat Rev Clin Oncol"},{"key":"4358_CR4","doi-asserted-by":"publisher","first-page":"189425","DOI":"10.1016\/j.bbcan.2025.189425","volume":"1880","author":"NN Chao","year":"2025","unstructured":"Chao NN, Zhang L (2025) Elucidating cellular origins and TME dynamic evolution in NSCLC through multi-omics technologies. Biochimica et Biophysica Acta (BBA) Rev. Cancer 1880:189425. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189425","journal-title":"Biochimica et Biophysica Acta (BBA) Rev. Cancer"},{"key":"4358_CR5","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1186\/s12885-019-6203-2","volume":"19","author":"H Xiao","year":"2019","unstructured":"Xiao H, He M, Xie G et al (2019) The release of tryptase from mast cells promote tumor cell metastasis via exosomes. BMC Cancer 19:1015. https:\/\/doi.org\/10.1186\/s12885-019-6203-2","journal-title":"BMC Cancer"},{"key":"4358_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12964-014-0064-8","volume":"12","author":"H Xiao","year":"2014","unstructured":"Xiao H, L\u00e4sser C, Shelke GV et al (2014) Mast cell exosomes promote lung adenocarcinoma cell proliferation - role of KIT-stem cell factor signaling. Cell Commun Signal 12:64. https:\/\/doi.org\/10.1186\/s12964-014-0064-8","journal-title":"Cell Commun Signal"},{"key":"4358_CR7","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1038\/s41598-025-91401-5","volume":"15","author":"M Zhang","year":"2025","unstructured":"Zhang M, Zhou G, Xu Y et al (2025) Immunogenic cell death signature predicts survival and reveals the role of VEGFA + mast cells in lung adenocarcinoma. Sci Rep 15:7213. https:\/\/doi.org\/10.1038\/s41598-025-91401-5","journal-title":"Sci Rep"},{"key":"4358_CR8","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.biomaterials.2016.10.023","volume":"112","author":"SG Oh","year":"2017","unstructured":"Oh SG, Li X, Lee HW et al (2017) Non-invasive visualization of mast cell recruitment and its effects in lung cancer by optical reporter gene imaging and glucose metabolism monitoring. Biomaterials 112:192\u2013203. https:\/\/doi.org\/10.1016\/j.biomaterials.2016.10.023","journal-title":"Biomaterials"},{"key":"4358_CR9","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1172\/JCI79840","volume":"125","author":"AD Giannou","year":"2015","unstructured":"Giannou AD, Marazioti A, Spella M et al (2015) Mast cells mediate malignant pleural effusion formation. J Clin Invest 125:2317\u20132334. https:\/\/doi.org\/10.1172\/JCI79840","journal-title":"J Clin Invest"},{"key":"4358_CR10","doi-asserted-by":"publisher","first-page":"6074","DOI":"10.1038\/s41467-025-61324-w","volume":"16","author":"F Fan","year":"2025","unstructured":"Fan F, Wang J, Liu K et al (2025) Mast cells boost anti-tumor potency of MAIT cells via inflammasome-dependent secretion of IL-18. Nat Commun 16:6074. https:\/\/doi.org\/10.1038\/s41467-025-61324-w","journal-title":"Nat Commun"},{"key":"4358_CR11","doi-asserted-by":"publisher","first-page":"106744","DOI":"10.1016\/j.intimp.2020.106744","volume":"86","author":"Z Pang","year":"2020","unstructured":"Pang Z, Chen X, Wang Y et al (2020) Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: development and validation of an individualized prognostic model. Int Immunopharmacol 86:106744. https:\/\/doi.org\/10.1016\/j.intimp.2020.106744","journal-title":"Int Immunopharmacol"},{"key":"4358_CR12","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/1759-7714.14654","volume":"13","author":"V Longo","year":"2022","unstructured":"Longo V, Catino A, Montrone M et al (2022) Controversial role of mast cells in NSCLC tumor progression and angiogenesis. Thorac Cancer 13:2929\u20132934. https:\/\/doi.org\/10.1111\/1759-7714.14654","journal-title":"Thorac Cancer"},{"key":"4358_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.62347\/EZST5505","volume":"14","author":"C Ligan","year":"2024","unstructured":"Ligan C, Ma XH, Zhao SL et al (2024) The regulatory role and mechanism of mast cells in tumor microenvironment. Am J Cancer Res 14:1\u201315. https:\/\/doi.org\/10.62347\/EZST5505","journal-title":"Am J Cancer Res"},{"key":"4358_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-immunol-071719-094903","volume":"38","author":"SJ Galli","year":"2020","unstructured":"Galli SJ, Gaudenzio N, Tsai M (2020) Mast cells in inflammation and disease: recent progress and ongoing concerns. Annu Rev Immunol 38:49\u201377. https:\/\/doi.org\/10.1146\/annurev-immunol-071719-094903","journal-title":"Annu Rev Immunol"},{"key":"4358_CR15","doi-asserted-by":"publisher","first-page":"108024","DOI":"10.1016\/j.pharmthera.2021.108024","volume":"233","author":"K Sumaiya","year":"2022","unstructured":"Sumaiya K, Langford D, Natarajaseenivasan K et al (2022) Macrophage migration inhibitory factor (MIF): a multifaceted cytokine regulated by genetic and physiological strategies. Pharmacol Ther 233:108024. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.108024","journal-title":"Pharmacol Ther"},{"key":"4358_CR16","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.drudis.2021.03.012","volume":"26","author":"A Osipyan","year":"2021","unstructured":"Osipyan A, Chen D, Dekker FJ (2021) Epigenetic regulation in macrophage migration inhibitory factor (MIF)-mediated signaling in cancer and inflammation. Drug Discov Today 26:1728\u20131734. https:\/\/doi.org\/10.1016\/j.drudis.2021.03.012","journal-title":"Drug Discov Today"},{"key":"4358_CR17","doi-asserted-by":"publisher","first-page":"110494","DOI":"10.1016\/j.intimp.2023.110494","volume":"121","author":"Z Liu","year":"2023","unstructured":"Liu Z, Li Z, Yan G et al (2023) MIF promotes Th17 cell differentiation in Hashimoto\u2019s thyroiditis by binding HVEM and activating NF-\u03baB signaling pathway. Int Immunopharmacol 121:110494. https:\/\/doi.org\/10.1016\/j.intimp.2023.110494","journal-title":"Int Immunopharmacol"},{"key":"4358_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s10020-024-01005-4","volume":"30","author":"G Yan","year":"2024","unstructured":"Yan G, Song R, Zhang J et al (2024) MIF promotes Th17 cell differentiation in rheumatoid arthritis through ATF6 signal pathway. Mol Med 30:237. https:\/\/doi.org\/10.1186\/s10020-024-01005-4","journal-title":"Mol Med"},{"key":"4358_CR19","doi-asserted-by":"publisher","first-page":"114959","DOI":"10.1016\/j.intimp.2025.114959","volume":"159","author":"F Zhang","year":"2025","unstructured":"Zhang F, Feng R, Meng T et al (2025) MIF regulates T helper 17 cell differentiation by activating the p38 MAPK signaling pathway to drive the pathogenesis of EAP. Int Immunopharmacol 159:114959. https:\/\/doi.org\/10.1016\/j.intimp.2025.114959","journal-title":"Int Immunopharmacol"},{"key":"4358_CR20","doi-asserted-by":"publisher","first-page":"17951","DOI":"10.18632\/oncotarget.24885","volume":"9","author":"K Mangano","year":"2018","unstructured":"Mangano K, Mazzon E, Basile MS et al (2018) Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach. Oncotarget 9:17951\u201317970. https:\/\/doi.org\/10.18632\/oncotarget.24885","journal-title":"Oncotarget"},{"key":"4358_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3390\/medicina58020190","volume":"58","author":"CK Balakrishnan","year":"2022","unstructured":"Balakrishnan CK, Tye GJ, Balasubramaniam SD et al (2022) CD74 and HLA-DRA in cervical carcinogenesis: potential targets for antitumour therapy. Medicina (Kaunas) 58:190. https:\/\/doi.org\/10.3390\/medicina58020190","journal-title":"Medicina (Kaunas)"},{"key":"4358_CR22","doi-asserted-by":"publisher","first-page":"1846915","DOI":"10.1080\/2162402X.2020.1846915","volume":"9","author":"RA de Azevedo","year":"2020","unstructured":"de Azevedo RA, Shoshan E, Whang S et al (2020) MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology 9:1846915. https:\/\/doi.org\/10.1080\/2162402X.2020.1846915","journal-title":"Oncoimmunology"},{"key":"4358_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1186\/s12935-024-03525-9","volume":"24","author":"MT Anvar","year":"2024","unstructured":"Anvar MT, Rashidan K, Arsam N et al (2024) Th17 cell function in cancers: immunosuppressive agents or anti-tumor allies? Cancer Cell Int 24:355. https:\/\/doi.org\/10.1186\/s12935-024-03525-9","journal-title":"Cancer Cell Int"},{"key":"4358_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/cancers14071681","volume":"14","author":"AC Pe\u00f1a-Romero","year":"2022","unstructured":"Pe\u00f1a-Romero AC, Orenes-Pi\u00f1ero E (2022) Dual effect of immune cells within tumour microenvironment: Pro- and anti-tumour effects and their triggers. Cancers (Basel) 14:1681. https:\/\/doi.org\/10.3390\/cancers14071681","journal-title":"Cancers (Basel)"},{"key":"4358_CR25","doi-asserted-by":"publisher","first-page":"7424","DOI":"10.3390\/ijms12117424","volume":"12","author":"S He","year":"2011","unstructured":"He S, Fei M, Wu Y et al (2011) Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 12:7424\u20137437. https:\/\/doi.org\/10.3390\/ijms12117424","journal-title":"Int J Mol Sci"},{"key":"4358_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jhep.2008.12.033","volume":"50","author":"JP Zhang","year":"2009","unstructured":"Zhang JP, Yan J, Xu J et al (2009) Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50:980\u2013989. https:\/\/doi.org\/10.1016\/j.jhep.2008.12.033","journal-title":"J Hepatol"},{"key":"4358_CR27","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1172\/JCI124037","volume":"130","author":"Y Salazar","year":"2020","unstructured":"Salazar Y, Zheng X, Brunn D et al (2020) Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. J Clin Invest 130:3560\u20133575. https:\/\/doi.org\/10.1172\/JCI124037","journal-title":"J Clin Invest"},{"key":"4358_CR28","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1073\/pnas.1319051111","volume":"111","author":"SH Chang","year":"2014","unstructured":"Chang SH, Mirabolfathinejad SG, Katta H et al (2014) T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci U S A 111:5664\u20135669. https:\/\/doi.org\/10.1073\/pnas.1319051111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4358_CR29","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/jnci\/djae120","volume":"116","author":"S Liu","year":"2024","unstructured":"Liu S, Rivero SL, Zhang B et al (2024) BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression. J Natl Cancer Inst 116:1598\u20131611. https:\/\/doi.org\/10.1093\/jnci\/djae120","journal-title":"J Natl Cancer Inst"},{"key":"4358_CR30","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1146\/annurev-immunol-101819-092536","volume":"39","author":"S Majumder","year":"2021","unstructured":"Majumder S, McGeachy MJ (2021) IL-17 in the pathogenesis of disease: Good intentions gone awry. Annu Rev Immunol 39:537\u2013556. https:\/\/doi.org\/10.1146\/annurev-immunol-101819-092536","journal-title":"Annu Rev Immunol"},{"key":"4358_CR31","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jtho.2017.04.017","volume":"12","author":"EA Akbay","year":"2017","unstructured":"Akbay EA, Koyama S, Liu Y et al (2017) Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade. J Thorac Oncol 12:1268\u20131279. https:\/\/doi.org\/10.1016\/j.jtho.2017.04.017","journal-title":"J Thorac Oncol"},{"key":"4358_CR32","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1158\/1078-0432.CCR-16-0617","volume":"23","author":"TJ Li","year":"2017","unstructured":"Li TJ, Jiang YM, Hu YF et al (2017) Interleukin-17-producing neutrophils link inflammatory stimuli to disease progression by promoting angiogenesis in gastric cancer. Clin Cancer Res 23:1575\u20131585. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0617","journal-title":"Clin Cancer Res"},{"key":"4358_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2195","volume":"10","author":"X Zhu","year":"2008","unstructured":"Zhu X, Mulcahy LA, Mohammed RA et al (2008) IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res 10:R95. https:\/\/doi.org\/10.1186\/bcr2195","journal-title":"Breast Cancer Res"},{"key":"4358_CR34","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1182\/blood-2009-05-220004","volume":"114","author":"S Piconese","year":"2009","unstructured":"Piconese S, Gri G, Tripodo C et al (2009) Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40\/OX40L axis toward Th17-cell differentiation. Blood 114:2639\u20132648. https:\/\/doi.org\/10.1182\/blood-2009-05-220004","journal-title":"Blood"},{"key":"4358_CR35","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.2147\/JIR.S509931","volume":"18","author":"E Leveque","year":"2025","unstructured":"Leveque E, Joulia R, Battut L et al (2025) Mast cells promote inflammatory Th17 cells and impair Treg cells through an IL-1\u03b2 and PGE2 axis. J Inflamm Res 18:5851\u20135865. https:\/\/doi.org\/10.2147\/JIR.S509931","journal-title":"J Inflamm Res"},{"key":"4358_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/eji.201040994","volume":"41","author":"A Dudeck","year":"2011","unstructured":"Dudeck A, Suender CA, Kostka SL et al (2011) Mast cells promote Th1 and Th17 responses by modulating dendritic cell maturation and function. Eur J Immunol 41:1883\u20131893. https:\/\/doi.org\/10.1002\/eji.201040994","journal-title":"Eur J Immunol"},{"key":"4358_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","volume":"79","author":"R Yu","year":"2022","unstructured":"Yu R, Zhu B, Chen D (2022) Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci 79:191. https:\/\/doi.org\/10.1007\/s00018-022-04219-z","journal-title":"Cell Mol Life Sci"},{"key":"4358_CR38","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJ Waugh","year":"2008","unstructured":"Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735\u20136741. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4843","journal-title":"Clin Cancer Res"},{"key":"4358_CR39","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura A, Kishimoto T (2010) IL-6: regulator of Treg\/Th17 balance. Eur J Immunol 40:1830\u20131835. https:\/\/doi.org\/10.1002\/eji.201040391","journal-title":"Eur J Immunol"},{"key":"4358_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","volume":"27","author":"T Korn","year":"2009","unstructured":"Korn T, Bettelli E, Oukka M et al (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485\u2013517. https:\/\/doi.org\/10.1146\/annurev.immunol.021908.132710","journal-title":"Annu Rev Immunol"},{"key":"4358_CR41","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/path.6018","volume":"259","author":"BL Woolbright","year":"2023","unstructured":"Woolbright BL, Rajendran G, Abbott E et al (2023) Role of MIF1\/MIF2\/CD74 interactions in bladder cancer. J Pathol 259:46\u201355. https:\/\/doi.org\/10.1002\/path.6018","journal-title":"J Pathol"},{"key":"4358_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.ejphar.2015.05.071","volume":"778","author":"T Zhang","year":"2016","unstructured":"Zhang T, Finn DF, Barlow JW et al (2016) Mast cell stabilisers. Eur J Pharmacol 778:158\u2013168. https:\/\/doi.org\/10.1016\/j.ejphar.2015.05.071","journal-title":"Eur J Pharmacol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04358-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04358-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T20:01:59Z","timestamp":1773518519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04358-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["4358"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04358-3","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"There are no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study involves human participants and was conducted using FFPE tissue specimens and clinical data from lung adenocarcinoma patients treated at Shanghai General Hospital. The study protocol was approved by the Institutional Review Board of Shanghai General Hospital (Project No: 2022KY011)\u00a0and\u00a0the Institutional Animal Care and Use Committee (IACUC) of Shanghai General Hospital\u00a0(Approval No. 2024AW060). All participants provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"104"}}